Long XQ, Liu MZ, Liu ZH, Xia LZ, Lu SP, Xu XP, Wu MH. Bile acids and their receptors: Potential therapeutic targets in inflammatory bowel disease. World J Gastroenterol 2023; 29(27): 4252-4270 [PMID: 37545642 DOI: 10.3748/wjg.v29.i27.4252]
Corresponding Author of This Article
Ming-Hao Wu, MM, Chief Doctor, Professor, Department of Gastroenterology, The First Affiliated Hospital of Hunan Normal University (Hunan Provincial People's Hospital), No. 61 Jiefang West Road, Furong District, Changsha 410005, Hunan Province, China. wuminghao1976@sina.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Xiong-Quan Long, Ming-Zhu Liu, Zi-Hao Liu, Lv-Zhou Xia, Shi-Peng Lu, Xiao-Ping Xu, Ming-Hao Wu, Department of Gastroenterology, The First Affiliated Hospital of Hunan Normal University (Hunan Provincial People's Hospital), Changsha 410005, Hunan Province, China
Author contributions: Long XQ performed the majority of the writing; Liu MZ, Liu ZH, Xia LZ, and Lu SP designed the outline and coordinated the writing of the paper; Wu MH and Xu XP edited and checked the manuscript; all of the authors have read and approved the final manuscript.
Supported byNational Natural Science Foundation of China, No. 81900466; and Hunan Provincial Natural Science Foundation of China, No. 2020JJ5307.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ming-Hao Wu, MM, Chief Doctor, Professor, Department of Gastroenterology, The First Affiliated Hospital of Hunan Normal University (Hunan Provincial People's Hospital), No. 61 Jiefang West Road, Furong District, Changsha 410005, Hunan Province, China. wuminghao1976@sina.com
Received: April 8, 2023 Peer-review started: April 8, 2023 First decision: May 12, 2023 Revised: May 19, 2023 Accepted: June 21, 2023 Article in press: June 21, 2023 Published online: July 21, 2023
Abstract
Chronic and recurrent inflammatory disorders of the gastrointestinal tract caused by a complex interplay between genetics and intestinal dysbiosis are called inflammatory bowel disease. As a result of the interaction between the liver and the gut microbiota, bile acids are an atypical class of steroids produced in mammals and traditionally known for their function in food absorption. With the development of genomics and metabolomics, more and more data suggest that the pathophysiological mechanisms of inflammatory bowel disease are regulated by bile acids and their receptors. Bile acids operate as signalling molecules by activating a variety of bile acid receptors that impact intestinal flora, epithelial barrier function, and intestinal immunology. Inflammatory bowel disease can be treated in new ways by using these potential molecules. This paper mainly discusses the increasing function of bile acids and their receptors in inflammatory bowel disease and their prospective therapeutic applications. In addition, we explore bile acid metabolism and the interaction of bile acids and the gut microbiota.
Core Tip: Chronic and recurrent inflammatory disorders of the gastrointestinal tract caused by a complex interplay between genetics and intestinal dysbiosis are called inflammatory bowel disease. With the development of genomics and metabolomics, more and more data suggest that bile acids operate as signalling molecules by activating a variety of bile acid receptors that regulate pathophysiological mechanisms of inflammatory bowel disease. Inflammatory bowel disease can be treated in new ways by using these potential molecules.
